Primary sclerosing cholangitis (PSC) is a rare, chronic, immune-mediated cholestatic liver disease characterized by inflammation, obliterative fibrosis, and multifocal stricturing of both the intrahepatic and extrahepatic biliary tree^1,3. The disease inexorably leads to chronic bile stasis, biliary cirrhosis, portal hypertension, and liver failure, with liver transplantation representing the sole definitive long-term therapy^2,4. PSC demonstrates a striking epidemiological and pathophysiological link with inflammatory bowel disease (IBD)—predominantly ulcerative colitis—affecting roughly 70% to 80% of individuals diagnosed with the condition^3,7. Furthermore, patients face a markedly elevated lifetime risk of developing hepatobiliary malignancies, particularly cholangiocarcinoma, as well as colorectal cancer in the setting of concurrent IBD^2,3.

Etiology & Risk Factors

• Genetic Predisposition: Strong association with human leukocyte antigen (HLA) alleles, notably HLA-B8, HLA-DR3, and HLA-DRB1*1301, alongside non-HLA genetic risk loci involving immune regulation and interleukin signaling pathways (e.g., IL2RA, IL2RB)^2,3,6.
• Inflammatory Bowel Disease (IBD): Coexists in 70% to 80% of PSC cases, most commonly manifesting as extensive ulcerative colitis (often with "backwash ileitis") or, less frequently, Crohn's colitis. PSC-associated IBD frequently exhibits a quiescent or right-sided predominant clinical phenotype^3,5,7.
• Demographics & Age of Onset: Predominantly affects young to middle-aged adults, showing a distinct male predominance with a male-to-female ratio ranging between 2:1 and 3:1⁴.
• Environmental and Microbial Factors: Emerging evidence highlights gut dysbiosis, increased intestinal permeability ("leaky gut"), and aberrant lymphocyte homing from the gut mucosal immune system to the liver via aberrant adhesion molecules (e.g., mucosal addressin cell adhesion molecule-1 [MAdCAM-1]) as critical triggers^3,6,7.
• Autoimmune Associations: Frequently overlaps with other autoimmune conditions, including autoimmune hepatitis (PSC-AIH overlap syndrome, more common in pediatric cohorts), type 1 diabetes mellitus, and celiac disease^1,6.

Pathophysiology

The pathogenesis of primary sclerosing cholangitis is driven by a complex interplay of genetic susceptibility, environmental triggers, and dysregulated immune responses targeting cholangiocytes^3,6. The proposed sequence begins when intestinal barrier dysfunction and gut dysbiosis permit bacterial antigens and microbial metabolites to translocation into the portal circulation. These pathogen-associated molecular patterns (PAMPs) and aberrant bile acid species stimulate toll-like receptors (TLRs) on portal fibroblasts and biliary epithelial cells, provoking local cytokine release (e.g., interleukins, tumor necrosis factor-alpha)^3,6,7.

Concurrently, aberrant activation of mucosal T-cells in the inflamed gut leads to aberrant lymphocyte homing to the liver, facilitated by vascular adhesion protein-1 (VAP-1) and MAdCAM-1 interactions. This promotes a robust, self-perpetuating cell-mediated immune response directed against the biliary epithelium⁶. Persistent inflammation stimulates profibrogenic pathways, particularly through transforming growth factor-beta (TGF-β) signaling and activation of hepatic stellate cells and portal myofibroblasts^2,4. This results in dense periductular concentric fibrosis—classically described as "onion-skinning"—around medium and large bile ducts⁴.

As the periductular collagenous tissue contracts, it progressively narrows the biliary lumen, leading to segmental strictures alternating with areas of normal or pre-stenotic ectasia, producing the classic "beaded" appearance on cholangiography^3,4. Chronic biliary outflow obstruction precipitates toxic intracellular hydrophobic bile acid accumulation within hepatocytes, generating oxidative stress, mitochondrial injury, and apoptotic cell death. Over years to decades, this relentless cycle of cholestasis, chronic cholangitis, and ductopenia culminates in secondary biliary fibrosis, bridging hepatic fibrosis, macronodular cirrhosis, and decompensated liver failure^3,4,7.

Clinical Presentation & Classic Clinical Signs

• History & Cardinal Symptoms:
  • Asymptomatic presentation occurs in up to 30% to 50% of patients at initial diagnosis, often discovered incidentally due to persistent, unexplained elevations in serum alkaline phosphatase^3,7.
  • Fatigue and intractable pruritus (itching) are among the earliest and most debilitating constitutional symptoms, often disproportionate to the degree of biochemical cholestasis^3,7.
  • Right upper quadrant abdominal pain and discomfort, resulting from biliary duct distension or stretching of Glisson's capsule.
  • Recurrent episodes of acute bacterial cholangitis, characterized by the classic Charcot's triad (fever/chills, right upper quadrant pain, and jaundice) or Reynolds' pentad (adding hypotension and altered mental status) in severe septic presentations^3,4.
  • Late-stage symptoms reflect decompensated cirrhosis and portal hypertension, including jaundice, dark urine, pale stools, peripheral edema, ascites, variceal gastrointestinal bleeding, and hepatic encephalopathy^3,7.
• Physical Examination & Named Clinical Signs:
  • Jaundice (icterus) of the sclerae and skin reflecting hyperbilirubinemia.
  • Excoriation marks from severe, chronic scratching due to generalized pruritus.
  • Hepatomegaly and splenomegaly upon abdominal palpation, secondary to portal hypertension and chronic hepatic congestion.
  • Cutaneous stigmata of chronic liver disease in advanced cases, including spider angiomata, palmar erythema, Dupuytren's contractures, and Terry's nails.
  • Signs of fat-soluble vitamin malabsorption (e.g., bruising from vitamin K deficiency, night blindness from vitamin A deficiency, or osteopenia/osteomalacia from vitamin D and calcium malabsorption).

Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Staging, Classification & Clinical Scoring Systems

Differential Diagnosis

Management & Treatment Protocol

• Initial Stabilization & Resuscitation:
  • Management of acute bacterial cholangitis requires immediate hospital admission, blood cultures, aggressive fluid resuscitation, and prompt administration of broad-spectrum intravenous antibiotics (e.g., piperacillin-tazobactam 3.375 g IV every 6 hours or ceftriaxone 2 g IV daily plus metronidazole 500 mg IV every 8 hours) followed by urgent biliary decompression via ERCP if obstruction is present^3,4.
  • Correction of coagulopathies and vitamin deficiencies resulting from fat-soluble vitamin malabsorption (administer Vitamin K 10 mg SC/IM daily for 3 days if INR is elevated; Vitamin D3 cholecalciferol 1,000–2,000 IU daily; calcium supplementation; and fat-soluble vitamins A, D, E, K monitoring)^1,3.
• First-Line Medical / Pharmacological Therapy (with exact adult dosing):
  • Ursodeoxycholic Acid (UDCA): Administered at low-to-moderate doses of 10 to 15 mg/kg/day orally divided twice daily. UDCA improves biochemical liver enzymes (ALP, ALT) and bile flow, but clinical trials have not definitively demonstrated improved transplant-free survival. Crucial Clinical Caveat: High-dose UDCA (28–30 mg/kg/day) is strictly contraindicated due to increased risk of serious adverse events, liver failure, and mortality^2,4.
  • Pruritus Management Protocol:
    • First-line: Cholestyramine resin 4 g orally mixed in water/juice before meals (maximum 16–24 g/day in divided doses), administered at least 4 hours apart from other medications to prevent binding interference.
    • Second-line: Rifampin 150 to 300 mg orally twice daily (monitor baseline and serial liver enzymes for hepatotoxicity).
    • Third-line: Naltrexone starting at 12.5 mg orally daily, titrating slowly up to 50 mg daily (caution for opioid withdrawal symptoms in patients on chronic opioids).
    • Refractory cases: Sertraline 50 to 100 mg orally daily or plasmapheresis/albumin dialysis in severe cases^1,3.
• Surgical / Interventional Indications:
  • Endoscopic Retrograde Cholangiopancreatography (ERCP) with Balloon Dilation: Indicated for symptomatic "dominant strictures" (stenoses < 1.5 mm in common bile duct or < 1.0 mm in hepatic ducts) causing worsening jaundice, recurrent cholangitis, or severe cholestasis. Routine stent placement is generally avoided unless short-term drainage is necessary, due to high risks of stent occlusion and secondary bacterial infection^3,4.
  • Orthotopic Liver Transplantation (OLT): The definitive, life-saving therapy for end-stage liver disease, refractory decompensated cirrhosis, intractable pruritus unresponsive to medical therapy, recurrent severe cholangitis, or high-grade dysplasia/early cholangiocarcinoma. PSC carries a notable recurrence rate of 15% to 30% in the graft years post-transplantation^1,2,3.

Complications & Prognosis

• Hepatobiliary Malignancies: Cholangiocarcinoma (CCA) develops in 10% to 20% of PSC patients over their lifetime, with an annual incidence of approximately 0.5% to 1.5%. Diagnosis is notoriously difficult due to overlapping features with benign strictures; surveillance involves serial carbohydrate antigen 19-9 (CA 19-9) serum testing and cross-sectional imaging (MRI/MRCP) every 6 to 12 months^2,3. Patients also carry an increased risk of gallbladder carcinoma (prompting prophylactic cholecystectomy if gallbladder polyps or masses are detected) and hepatocellular carcinoma in the presence of cirrhosis^1,3.
• Colorectal Neoplasia: Patients with PSC and concurrent IBD have a significantly elevated risk of developing colorectal dysplasia and colorectal adenocarcinoma compared to patients with IBD alone. Surveillance requires annual screening colonoscopies with random and targeted mucosal biopsies, irrespective of IBD disease activity^2,3,7.
• Metabolic Bone Disease: Osteopenia and osteoporosis occur frequently due to chronic cholestasis, vitamin D malabsorption, and chronic systemic inflammation, increasing fracture risk and necessitating baseline DEXA scanning and bisphosphonate therapy when indicated^1,3.
• Biliary Cirrhosis and Portal Hypertension: Progressive ductopenia and fibrosis lead to secondary biliary cirrhosis, resulting in complications including ascites, esophageal variceal hemorrhage, hepatic encephalopathy, and hypersplenism^3,4.
• Prognosis: The natural history of PSC is highly variable, with a median transplant-free survival from time of diagnosis ranging between 12 and 20 years, though prognosis is heavily dictated by the development of dominant strictures, cholangiocarcinoma, and end-stage liver failure^2,3,7.